Franklin-1 · protein crystallization
Franklin-1 is designed to fly sealed crystallization experiments. Pathfinder is unbuilt and funding-gated. ADHD actives (~$15–20B+ a year) look almost unstudied in microgravity despite being small-molecule formulation problems: polymorph, particle size, release kinetics.
No clear published crystallization campaigns on methylphenidate, amphetamine salts, lisdexamfetamine, atomoxetine, or guanfacine. The same convection-free growth that helps other small molecules applies here.
Design: dual-reservoir cartridge, ultrasonic mixing, thermal control, optical monitoring, data-first downlink. Pathfinder targeted 2027, partner- and funding-gated.
Download ADHD research brief (PDF)